Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18911506 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | October 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18049105 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | October 2022 | April 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17936006 | T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3 | September 2022 | May 2025 | Allow | 32 | 1 | 0 | No | No |
| 17933298 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17933353 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17930891 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17929347 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17929344 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17822653 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | August 2022 | May 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17820821 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | August 2022 | January 2025 | Allow | 29 | 1 | 0 | No | No |
| 17820824 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | August 2022 | February 2025 | Allow | 30 | 1 | 0 | No | No |
| 17820432 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | August 2022 | March 2025 | Allow | 31 | 2 | 0 | No | No |
| 17819470 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | August 2022 | December 2024 | Allow | 28 | 1 | 0 | No | No |
| 17886752 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | August 2022 | January 2025 | Allow | 29 | 1 | 0 | No | No |
| 17877535 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17871724 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2022 | December 2024 | Allow | 29 | 1 | 0 | No | No |
| 17847094 | PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAME | June 2022 | March 2025 | Allow | 33 | 2 | 1 | No | No |
| 17693316 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | March 2022 | June 2022 | Allow | 4 | 0 | 0 | No | No |
| 17653846 | BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | March 2022 | February 2025 | Allow | 35 | 2 | 0 | No | No |
| 17687307 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | March 2022 | July 2022 | Allow | 4 | 0 | 0 | No | No |
| 17681107 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | February 2022 | June 2022 | Allow | 3 | 0 | 0 | No | No |
| 17674910 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | February 2022 | June 2022 | Allow | 3 | 0 | 0 | No | No |
| 17669601 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | February 2022 | April 2022 | Allow | 2 | 0 | 0 | No | No |
| 17665199 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | February 2022 | April 2022 | Allow | 2 | 0 | 0 | No | No |
| 17587387 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | January 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17581260 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | January 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17576714 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | January 2022 | November 2022 | Allow | 10 | 0 | 0 | No | No |
| 17570943 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | January 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17561051 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | December 2021 | April 2022 | Allow | 4 | 0 | 0 | No | No |
| 17556019 | Neoantigen Peptide Mimics | December 2021 | December 2024 | Allow | 36 | 5 | 1 | Yes | No |
| 17532613 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION | November 2021 | May 2025 | Abandon | 42 | 4 | 0 | No | No |
| 17530443 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | November 2021 | March 2022 | Allow | 4 | 0 | 0 | No | No |
| 17525196 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | November 2021 | March 2022 | Allow | 4 | 0 | 0 | No | No |
| 17611119 | COMPOSITIONS AND METHODS TO BLOCK AND BIND CCR2 TO MODULATE CELLULAR FUNCTION | November 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
| 17520097 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | November 2021 | March 2022 | Allow | 4 | 0 | 0 | No | No |
| 17514822 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | October 2021 | March 2022 | Allow | 4 | 0 | 0 | No | No |
| 17503020 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17478036 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | September 2021 | February 2022 | Allow | 5 | 0 | 0 | No | No |
| 17477869 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2021 | March 2022 | Allow | 5 | 0 | 0 | No | No |
| 17472293 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | September 2021 | March 2022 | Allow | 6 | 0 | 0 | No | No |
| 17465460 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | September 2021 | January 2022 | Allow | 5 | 0 | 0 | No | No |
| 17465597 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | September 2021 | February 2022 | Allow | 5 | 0 | 0 | No | No |
| 17464565 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | September 2021 | June 2022 | Allow | 10 | 2 | 0 | No | No |
| 17459155 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | August 2021 | May 2022 | Allow | 8 | 1 | 0 | No | No |
| 17459150 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | August 2021 | April 2022 | Allow | 7 | 1 | 0 | No | No |
| 17401720 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | August 2021 | April 2022 | Allow | 8 | 1 | 0 | No | No |
| 17396377 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | August 2021 | May 2022 | Allow | 9 | 0 | 0 | No | No |
| 17396345 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | August 2021 | February 2022 | Allow | 6 | 1 | 0 | No | No |
| 17390516 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | July 2021 | February 2022 | Allow | 7 | 1 | 0 | No | No |
| 17390503 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | July 2021 | April 2022 | Allow | 8 | 1 | 0 | No | No |
| 17384330 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | July 2021 | April 2022 | Allow | 8 | 1 | 0 | No | No |
| 17377867 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2021 | December 2021 | Allow | 5 | 0 | 0 | No | No |
| 17377905 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2021 | October 2021 | Allow | 3 | 0 | 0 | No | No |
| 17371826 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2021 | November 2021 | Allow | 4 | 0 | 0 | No | No |
| 17371871 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | July 2021 | November 2021 | Allow | 4 | 0 | 0 | No | No |
| 17366894 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | July 2021 | March 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17350964 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | June 2021 | September 2021 | Allow | 3 | 0 | 0 | No | No |
| 17345211 | NOEVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | June 2021 | October 2021 | Allow | 4 | 0 | 0 | No | No |
| 17339303 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | June 2021 | October 2021 | Allow | 4 | 0 | 0 | No | No |
| 17333994 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | May 2021 | September 2021 | Allow | 4 | 0 | 0 | No | No |
| 17297806 | SUBSTANCE FOR TREATING AND/OR PREVENTING TUMORS, AND DESIGN METHOD AND PREPARATION METHOD THEREOF | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17327487 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | May 2021 | October 2021 | Allow | 5 | 0 | 0 | No | No |
| 17245076 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | April 2021 | November 2021 | Allow | 7 | 1 | 0 | No | No |
| 17245105 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | April 2021 | October 2021 | Allow | 5 | 0 | 0 | No | No |
| 17229447 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | April 2021 | August 2021 | Allow | 4 | 0 | 0 | No | No |
| 17229411 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | April 2021 | July 2021 | Allow | 3 | 0 | 0 | No | No |
| 17227885 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | April 2021 | July 2021 | Allow | 3 | 0 | 0 | No | No |
| 17200729 | METHODS FOR DIAGNOSING AND TREATING CANCERS | March 2021 | February 2025 | Allow | 47 | 5 | 1 | Yes | Yes |
| 17155494 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | January 2021 | June 2021 | Allow | 60 | 0 | 0 | No | No |
| 17155468 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | January 2021 | June 2021 | Allow | 5 | 0 | 0 | No | No |
| 17150110 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | January 2021 | June 2021 | Allow | 5 | 0 | 0 | No | No |
| 17150257 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | January 2021 | June 2021 | Allow | 5 | 0 | 0 | No | No |
| 17124185 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | December 2020 | April 2021 | Allow | 4 | 0 | 0 | No | No |
| 17117611 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | December 2020 | March 2021 | Allow | 3 | 0 | 0 | No | No |
| 17117188 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | December 2020 | April 2021 | Allow | 4 | 0 | 0 | No | No |
| 17117191 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | December 2020 | April 2021 | Allow | 4 | 0 | 0 | No | No |
| 17116635 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | December 2020 | April 2021 | Allow | 4 | 0 | 0 | No | No |
| 17097692 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | March 2021 | Allow | 4 | 0 | 0 | No | No |
| 17097798 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | March 2021 | Allow | 4 | 0 | 0 | No | No |
| 17089330 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | January 2021 | Allow | 3 | 0 | 0 | No | No |
| 17089353 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | January 2021 | Allow | 3 | 0 | 0 | No | No |
| 17089279 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | January 2021 | Allow | 2 | 0 | 0 | No | No |
| 17089486 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | February 2021 | Allow | 3 | 0 | 0 | No | No |
| 17089502 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | March 2021 | Allow | 4 | 0 | 0 | No | No |
| 17089499 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | November 2020 | February 2021 | Allow | 4 | 0 | 0 | No | No |
| 17039032 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | September 2020 | December 2020 | Allow | 2 | 0 | 0 | No | No |
| 17039122 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | September 2020 | January 2021 | Allow | 3 | 0 | 0 | No | No |
| 17017281 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | September 2020 | March 2021 | Allow | 6 | 1 | 0 | No | No |
| 17005039 | Anti-CD38 Antibodies for Treatment of Acute Myeloid Leukemia | August 2020 | January 2025 | Allow | 52 | 5 | 0 | No | No |
| 16998162 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | August 2020 | March 2021 | Allow | 7 | 1 | 0 | No | No |
| 16917211 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | June 2020 | December 2020 | Allow | 5 | 0 | 0 | No | No |
| 16917263 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | June 2020 | February 2021 | Allow | 7 | 0 | 0 | No | No |
| 16915465 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | June 2020 | March 2021 | Allow | 9 | 1 | 0 | No | No |
| 16913820 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | June 2020 | November 2020 | Allow | 4 | 0 | 0 | No | No |
| 16914088 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | June 2020 | October 2020 | Allow | 4 | 0 | 0 | No | No |
| 16914059 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | June 2020 | October 2020 | Allow | 3 | 0 | 0 | No | No |
| 16913856 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | June 2020 | November 2020 | Allow | 5 | 0 | 0 | No | No |
| 16913938 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | June 2020 | November 2020 | Allow | 5 | 0 | 0 | No | No |
| 16913788 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | June 2020 | January 2021 | Allow | 6 | 1 | 0 | No | No |
| 16914135 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | June 2020 | February 2021 | Allow | 8 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUFF, SHEELA JITENDRA.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUFF, SHEELA JITENDRA works in Art Unit 1643 and has examined 1,228 patent applications in our dataset. With an allowance rate of 72.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner HUFF, SHEELA JITENDRA's allowance rate of 72.0% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HUFF, SHEELA JITENDRA receive 1.46 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUFF, SHEELA JITENDRA is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +10.2% benefit to allowance rate for applications examined by HUFF, SHEELA JITENDRA. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 29.9% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 62.4% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 77.5% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 80.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 75.6% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.7% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.